Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.34 |
| ▸ | RAF1 | P04049 | 4/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25115078 | 1.00 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25115027 | 1.00 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25114637 | 1.00 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25114909 | 0.96 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25114886 | 0.96 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25113928 | 0.96 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL25115960 | 0.93 | GABRA5 (0.33) | CFTRRAF1BRAFGABRA5 | |
| SCHEMBL25117150 | 0.93 | GABRA5 (0.33) | CFTRRAF1BRAFGABRA5 | |
| SCHEMBL24986244 | 0.92 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 | |
| SCHEMBL24986247 | 0.92 | CFTR (0.34) | CFTRRAF1BRAFGABRA5ADCY8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | CFTR 283/4885RAF1 3626/4885BRAF 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.